Leo Cancer Care's upright radiotherapy platform gains clinical clearance, marking a pivotal transition from conceptual design to practical application in oncology treatment.
The company's upright radiotherapy platform received clearance for clinical use with any radiation beam, marking a significant commercial milestone.
Leo Cancer Care has achieved a major commercial milestone as its upright radiotherapy platform receives clearance for clinical use. The system's beam-agnostic design allows for integration with various radiation sources, signaling a shift in oncology treatment standards.
The clearance validates the company's upright radiotherapy platform for clinical use, allowing it to be deployed with any radiation beam and moving the technology from a conceptual phase to active clinical application.